Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors

Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors

There are limited data on duration of aromatase inhibitor (AI) and cardiovascular disease (CVD) risk in breast cancer (BC) survivors. We examined risk of CVD and mortality associated with duration of AI use in postmenopausal women with early-stage hormone receptor-positive BC. Postmenopausal women d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI cancer spectrum 2025-01
Hauptverfasser: Huang, Yuhan, Kwan, Marilyn L, Heckbert, Susan R, Smith, Nicholas L, Othus, Megan, Laurent, Cecile A, Roh, Janise M, Rillamas-Sun, Eileen, Lee, Valerie S, Kolevska, Tatjana, Cheng, Richard K, Irribarren, Carlos, Nguyen-Huynh, Mai, Hershman, Dawn L, Kushi, Lawrence H, Greenlee, Heather
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:There are limited data on duration of aromatase inhibitor (AI) and cardiovascular disease (CVD) risk in breast cancer (BC) survivors. We examined risk of CVD and mortality associated with duration of AI use in postmenopausal women with early-stage hormone receptor-positive BC. Postmenopausal women diagnosed with hormone receptor-positive BC (n = 5,853) who used an AI were included. Cause-specific hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between AI use duration (short-term: >0 and
ISSN:2515-5091
2515-5091
DOI:10.1093/jncics/pkaf009